Novo Nordisk A/S’s latest experimental obesity drug helped patients lose as much as 24.3% of their weight in a small study, ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

By Diana Novak Jones (Reuters) -A federal judge has rejected a bid by compounding pharmacies to allow them to continue making ...

Top Alternatives to Ozempic That Are EffectiveReviewed by Dr. Craig Primack, MD, FACP, FAAP, FOMAOzempic is a medication ...

THIS VIDEO CONTAINS CONTENT SOME PEOPLE MAY FIND DISTRESSING“There is this one kid who called me pregnant because of my ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

Novo Nordisk A/S's NVO semaglutide, a GLP-1 receptor agonist, is the active substance in certain medicines used for diabetes and obesity (Ozempic, Rybelsus, and Wegovy). After reviewing all ...

Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration ...